Geneva, Switzerland, January 5, 2024 – 6:00 p.m. CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), biopharmaceutical company whose objective is to stop the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis ( MS), amyotrophic lateral sclerosis (ALS), and post-acute sequelae of COVID-19 (PAASC, long COVID or post-COVID), today announced the appointment of Anke Post, MD, PhD, as Director Chief Medical Officer, effective today, following the retirement of David Leppert, MD.
Professor David Leppert, Chief Medical Officer of GeNeuro since April 2020, has played a pivotal role in promoting temelimab as a neurodegeneration-focused drug candidate in multiple sclerosis and in launching GeNeuro’s post-COVID initiative. the society. After his retirement, he will continue as a consultant to support GeNeuro in its mission to introduce temelimab to MS patients. Temelimab aims to complement current treatments, which offer only minimal effect in preventing long-term disability in MS patients.